---
title: "InSilico Medicine Grants 3.7 Million RSUs to Boost Retention and Performance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282688311.md"
description: "InSilico Medicine Cayman TopCo has granted 3,706,886 restricted share units (RSUs) to eligible employees under its Post-IPO RSU Scheme, with no purchase price based on a share price of HK$60.35. The RSUs are divided into special and regular tranches, with multi-year vesting schedules linked to performance criteria. This initiative aims to retain high-performing staff and enhance operational execution. InSilico Medicine is a Hong Kong-listed biotechnology firm focused on drug discovery and development, targeting the global pharmaceutical market."
datetime: "2026-04-14T12:08:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282688311.md)
  - [en](https://longbridge.com/en/news/282688311.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282688311.md)
---

# InSilico Medicine Grants 3.7 Million RSUs to Boost Retention and Performance

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

InSilico Medicine Cayman TopCo ( (HK:3696) ) has shared an update.

InSilico Medicine Cayman TopCo has granted 3,706,886 restricted share units to eligible employees under its Post-IPO RSU Scheme, with no purchase price and based on a share closing price of HK$60.35 on the grant date. The awards are split into special and regular tranches, each with structured multi-year vesting schedules tied to minimum 12‑month periods and ongoing performance criteria.

The remuneration committee said the grant structure is designed to be market-competitive and closely aligned with the scheme’s objective of rewarding strong past performance and incentivizing long-term commitment. By linking vesting to both tenure and annual performance reviews, the company aims to retain high-performing staff, reinforce leadership and technical continuity, and strengthen its operational and strategic execution capacity over time.

**More about InSilico Medicine Cayman TopCo**

InSilico Medicine Cayman TopCo is a Hong Kong-listed biotechnology company focused on drug discovery and development, leveraging advanced technologies to create novel therapeutics. The company operates in the life sciences sector, targeting global pharmaceutical and healthcare markets with innovation-driven research and development capabilities.

**Average Trading Volume:** 2,840,683

**Current Market Cap:** HK$35.55B

See more insights into 3696 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [09:00 ETGenerative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE](https://longbridge.com/en/news/284007341.md)
- [InSilico Medicine Wins China IND Nod for AI-Discovered IPF Drug Rentosertib](https://longbridge.com/en/news/284467539.md)
- [20:00 ETLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma](https://longbridge.com/en/news/286687690.md)
- [InSilico Expands AI-Driven CNS Collaboration With Tenacia in USD94.75 Million Deal](https://longbridge.com/en/news/280541264.md)
- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)